Drug-Pricing Help Wanted: Wyden, Grassley Seek Public Input On Policy Ideas
This article was originally published in The Pink Sheet Daily
Following their 2015 report on Gilead's pricing methodology for Sovaldi and Harvoni, senators ask for comments on how to measure value and improve price transparency.
You may also be interested in...
Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.